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Dose-response relationships for raised cytoplasmic free calcium concentration, [Ca2+],, and shape change 
were measured simultaneously in quinZloaded human platelets. With the calcium ionophore ionomycin the 
threshold [Ca2+], for shape change was 300 nM with a maximal response at 800 nM. With 1 mM external 
Ca2+ the U44069 concentrations required to stimulate half-maximal shape change and an increase in [Ca2+], 
were 2 and 41 nM, respectively. For PAF these values were 8.7 and 164 pg/ml, respectively. Low concentra- 
tions of U44069 and PAF evoked substantial shape change without any rise in [Caz+],. In the absence of 
external Ca2+, U44069 stimulated half-maximal shape change at 2 nM, and half-maximal elevation of [Ca2+], 
at 69 nM: here, increased [Ca2+], never reached the threshold [Caz+], for shape change derived with ionomy- 
tin. These results suggest hat some transduction mechanism other than elevated [Ca2+],, as yet unidentified, 
can cause shape change. 
U44069 Ionomycin Ca2+ Shapechange Platelet Platelet-activating factor 
1. INTRODUCTION 
Within seconds after addition of an agonist such 
as thrombin, platelet-activating factor (PAF) or 
prostaglandin endoperoxide, platelets change 
shape from smooth discs to spiny spheres. Many 
cellular processes are associated with these changes 
including repositioning of the equatorial band of 
microtubules, polymerisation of actin, phosphory- 
lation of myosin light chains, formation of ac- 
tomyosin, centralisation of secretory granules and 
formation of filopodia and pseudopodia [l-4]. 
One link between the binding of an agonist to its 
receptor and these events appears to be a rise 
in cytoplasmic free calcium ([Ca’+]i). Indeed, 
calcium ionophores are effective stimuli for shape 
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change [5,6]. In quin2-loaded platelets, treated 
with varying concentrations of the Ca2+ ionophore 
ionomycin, a 3-fold rise in [Ca’+]i to about 
300 nM was found to be the apparent hreshold for 
shape change [7,8]. Maximal shape change oc- 
curred when [Ca’+]i was elevated to between 600 
and 800 nM. Physiological agonists that cause 
shape change also elevate [Ca’+]i sufficiently for 
this rise to cause shape change [7-91. 
In Ca2+-free media, with 1 mM EGTA, where 
the cytoplasmic buffering has been increased by 
quin2, optimal concentrations of agonists or 
ionophore elevate [Ca2+]i to no more than 200 nM 
[8,9]. Under these conditions Ca2+ ionophores, as 
expected, do not cause shape change; yet agonists 
added alone or after the ionophore do cause shape 
change and myosin light chain phosphorylation 
[7-9,111. We have interpreted such results to in- 
dicate that signal transduction systems other than 
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elevated [Ca’+]i, available to agonists but not to 
ionomycin, can trigger shape change. Such studies 
have been carried out using maximal concentration 
of agonists in the absence of extracellular Ca2+. 
Here, we have studied the relationship between the 
concentration of agonists U44069 and PAF and 
their ability to evoke shape change and elevate 
[Ca’+]i in the presence as well as absence of exter- 
nal Ca2+. 
We have shown that under conditions pertinent 
to those encountered in vivo, i.e. 1 mM Ca2+ and 
low agonist concentrations, shape change can be 
stimulated while [Ca’+]i, as measured by quin2, re- 
mains at basal levels and that the EC50 for agonist- 
stimulated shape change is independent of [Ca2+]i. 
2. EXPERIMENTAL 
Human platelet-rich plasma (PRP) was isolated 
from freshly drawn blood and incubated with 
15 PM quin2 AM following the method in [12]. 
5 min before the end of the incubation 1OOpM 
aspirin and 40pg/ml apyrase were added to the 
PRP. The cells were resuspended in a Hepes- 
buffered physiological saline containing: 145 mM 
NaCl, 5 mM KCl, 1 mM MgS04, 10 mM Hepes, 
10 mM dextrose (pH 7.4) at 37°C. The cell suspen- 
sion also contained 0.05 U/ml hirudin and 
20 pg/ml apyrase. Before measurements were 
made, aliquots of the cell suspension were 
equilibrated to 37°C for several minutes and the 
external calcium concentration adjusted by adding 
1 mM CaCl2 or 1 mM NazHzEGTA as required. 
Quin2 fluorescence was monitored in a continually 
stirred cell suspension, thermostatted to 37°C in a 
Perkin Elmer MPF 44A spectrofluorimeter. The 
instrument was adapted so that the absorbance of 
the stirred suspension could be monitored produc- 
ing a turbidometric trace like that produced in a 
standard aggregometer simultaneously with 
fluorescence [13]. The quin2 fluorescence signal 
was calibrated as described [12,14]. 
Calcium-selective lectrodes were constructed by 
fusing Ca2+ -selective PVC matrix membranes up- 
plied by Pye Unicam (part no. 9436 094 75861) on- 
to 1 mm PVC tubing with tetrahydrofuran. The 
reference electrode consisted of a similar tube 
filled with 3 M KC1 gelled in agar. The potential 
difference was measured by a specially constructed 
high independence lectrometer and the electrode 
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calibrated in a series of Ca2+ buffers containing 
free Ca2+ in the range 10-7-10-3 M [15]. 
Shape change was expressed as % maximal 
deflection in absorbance recorded on the chart 
recorder. Dose-response curves were fitted to the 
logistic equation by computer using the ALLFIT 
program [la]. The points are means f SE. Errors 
quoted for EC50 values are approximate SE de- 
rived from this fitting procedure. 
Apyrase type I and aspirin (acetylsalicylic acid) 
were obtained from Sigma; EGTA puriss from 
Fluka; quin2 AM from Lancaster synthesis; 
U44069 from the Upjohn Co., Kalamazoo and 
PAF from Calbiochem. 
3. RESULTS AND DISCUSSION 
Fig.1 shows the relation between increases in 
[Ca”], and shape change. 200 nM of the Ca2+ 
ionophore ionomycin was added to platelet 
suspensions with varying external Ca2+ concentra- 
tions. With low external Ca2+ there was a small in- 
crease in [Ca’+]i with no shape change. As the ex- 
ternal Ca2+ was increased so did the increase in 
[Ca2+]i and shape change occurred. The threshold 
[Ca”], for this response was 300 nM with a max- 
imal response occurring at 0.8-l PM. The same 
relationship between [Ca2+]i and shape change was 
observed when external Ca2+ was held constant at 
1 mM and the ionomycin concentration varied. 
Fig. 1, Effect of varying the external Ca*+ concentration 
on ionomycin (200 nM) induced elevation of [Ca”], and 
shape change. A(Ca*+], is the measured increment over 
the resting level. Shape change is measured as the % of 
the maximal increment in absorbance. The external Ca2+ 
concentration was varied by adding varying 
concentrations of EGTA or CaCl2 to the platelet 
suspension. 
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Fig.2. Simultaneous measurements of [Ca’+]i and 
absorbance of platelets timulated with U44069. The 
figure shows the effect of three concentrations of 
U44069 on [Ca*+]i and absorbance in-the presence of 
1 mM extracellular Ca*+_ 
Fig.2 shows the effect of adding U44069 at three 
different concentrations in the presence of 1 mM 
external Ca2+. 6 nM II44069 produced no incre- 
ment in fCa”]i, but was an effective stimulus for 
shape change. Increasing the U44069 concentra- 
tion to 30 nM and 1 PM produces no further incre- 
ment in the absorbance signal although [Ca’+]i is 
now markedly increased. Scanning electron 
micrographs confirm that the cells which are nor- 
mally in a discoid resting state do undergo shape 
changes as indicated by the increase in absorbance 
of the suspension. Fig.3A shows the collected data 
from experiments like those in fig.2. The 
calculated EC50 is 1.8 f 0.2 nM for shape change 
and 41 f 6 nM for elevation of [Ca*+]i; shape 
change is maximal at the threshold concentration 
for the [Ca2+)i rise. 
Fig.3B shows the collected data from ex- 
periments with U44069 conducted in Ca2+-free 
solution containing 1 mM EGTA. The EC& for 
shape change is 2.0 + 0.1 nM and that for the 
[Ca2+]i rise is 69 + 12 nM. Again the shape change 
is maximal at the threshold for the [Ca2+]i rise. 
One important point is that while the EC50 values 
for the [Ca’+]i rise are similar in the presence and 
absence of external Ca’+, the maximal [Ca*‘]i rise 
in the presence of 1 mM Ca2+, 1500 nM, is very 
much larger than the rise in the absence of external 
Ca2+ , 100 nM. For shape change both the ECSO 
A InMCa. 
Fig.3. Dose-response relation for U~9-induced shape 
change and inurement in [Ca**]r above resting levels. (A) 
In the presence of 1 mM extracellutar Ca’+. (B) In the 
presence of 1 mM extracellular EGTA with no added 
Ca’+. 
and extent of the response are similar in the 
presence and absence of calcium judged from the 
absorbance measurements and from scanning elec- 
tron microscopy (not shown). 
Similar results were also obtained for PAF- 
induced shape change and elevation of [Ca*+]i. In 
the presence of 1 mM extracellular CaZf the ECS~ 
values were 8.7 + 1.8 and 164 f 53 pg/ml PAF, 
respectively. With 1 mM EGTA present the EC50 
value for shape change was 10.6 4 1.2 pg/ml and 
for elevation of [Ca’+]i was 65 f 11 pg/ml. As 
with U44069, the dose-response curve for elevation 
of [Ca2+]t lies well to the right of that for shape 
change and again the EC50 values for shape change 
are the same in the presence and absence of ex- 
tracellular Ca2+ when [Ca2+]i is quite different. 
Our data show that the dose-response relation 
for U44069 and PAF-induced elevation of [Ca2’]i 
is markedly to the right of that for shape change 
and that these agonists can induce shape change 
while measured [Ca2+]i remains unchanged at the 
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resting level. This suggests that a rise in [Ca2+]i is 
not a necessary stimulus, although an imposed rise 
in [Ca2+]i can be a sufficient stimulus, for shape 
change. 
Furthermore the similar dose-response relation- 
ship for shape change in the presence and absence 
of external Ca’+, where the change in [Ca2+]i is 
very different, suggests that mechanisms other 
than a rise in [Ca’+]i can promote the observed 
changes in shape. An alternate view is that a 
privileged pool of intracellular Ca’+, not requiring 
external calcium, inaccessible to calcium 
ionophore, and immune from the buffering power 
of quin2, is responsible for the effects. 
The finding that a dose-effect curve lies to the 
left of the agonist binding curve is often considered 
in terms of spare receptors. This analysis usually 
assumes that only a small proportion of receptors 
is needed to generate the second message or that 
only a small amount of second message is required 
to produce the observed effect. Clearly only the 
second possibility applies in the present case if the 
second messenger isCa2+, and from the arguments 
above this seems not to be plausible. Our proposal 
that another transduction pathway is operating 
also supposes that only a small fraction of the 
receptors need be occupied for this pathway to be 
effective. Whether this is a small proportion of a 
homogeneous population of receptors or a limited 
number of high-affinity receptors with special 
properties cannot be determined from the available 
data. However, data from binding studies [17] sug- 
gest it is likely that less than 5% of the saturable 
binding sites for U44069 would be occupied at the 
ECS~, 2 nM, for U44069-induced shape change. 
Two recent reports [18,19] have suggested that 
either diacylglycerol or phosphatidylinositol 
4,5-bisphosphate may play a part in forming a 
nucleation site for the polymerisation of actin 
which forms the microfilaments in pseudopodia. 
According to existing data [ 171 there would be little 
stimulation of inositol lipid turnover at the U44069 
concentrations which we find to cause shape 
change without a measurable rise in [Ca’+]r. It is 
unclear whether this would be sufficient for the 
formation of nucleation sites. Changes in cyclic 
nucleotide levels or in cytoplasmic pH are unlikely 
to be involved. CAMP and cGMP are inhibitors of 
platelet function [20,21], and cytoplasmic pH 
changes less than 0.05 units following stimulation 
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with U44069, assessed from the fluorescence 
of trapped biscarboxyethylcarboxyfluorescein 
(Hallam, Simpson and Rink, unpublished). At pre- 
sent the nature of the putative alternative transduc- 
tion mechanism remains unclear. 
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